Abstract
Stiripentol (Diacomit®) is an orally-active, structurally unique anti-epileptic drug (AED) with multiple potential mechanisms of action, including enhancement of central γ-aminobutyric acid transmission. In the EU, stiripentol is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with Dravet syndrome (DS; previously known as severe myoclonic epilepsy of infancy), whose seizures are not adequately controlled with clobazam and valproate. This approval (and similar DS indications in the USA, Canada and Japan), reflect the results of the STICLO studies, two small, randomized controlled trials in which stiripentol as adjunctive therapy was associated with a markedly superior response rate after 2 months compared with placebo in patients aged between 3 and ≈ 21 years with DS that was inadequately controlled with clobazam and valproate. These short-term results have subsequently been supported and extended by findings from longer-term, open-label, observational studies, including a retrospective longitudinal cohort study, which showed that the efficacy of combining stiripentol with clobazam and valproate when started at paediatric age was maintained in mid-adulthood with up to 24 years of exposure, and up to 40 years of age. Drowsiness, appetite loss, weight loss, ataxia and tremor are the most common adverse events associated with the addition of stiripentol to clobazam and valproate. Based on the available evidence, stiripentol, as an adjunct to clobazam and valproate, is a demonstrably beneficial and generally well-tolerated second-line treatment for patients with DS.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs40265-019-01204-y/MediaObjects/40265_2019_1204_Fig1_HTML.png)
Similar content being viewed by others
References
Dravet C, Bureau M, Oguni H, et al. Severe myoclonic epilepsy in infancy: Dravet syndrome. In: Roger J, Bureau M, Dravet C, et al., editors. Epileptic syndromes in infancy, childhood and adolescence. Montrouge: John Libbey Eurotext Ltd.; 2005. p. 89–113.
Wu YW, Sullivan J, McDaniel SS, et al. Incidence of Dravet syndrome in a US population. Pediatrics. 2015;136(5):e1310.
Gataullina S, Dulac O. From genotype to phenotype in Dravet disease. Seizure. 2017;44:58–64.
Genton P, Velizarova R, Dravet C. Dravet syndrome: the long-term outcome. Epilepsia. 2011;52(Suppl 2):44–9.
Cooper MS, McIntosh A, Crompton DE, et al. Mortality in Dravet syndrome. Epilepsy Res. 2016;128:43–7.
Knupp KG, Wirrell EC. Treatment strategies for Dravet syndrome. CNS Drugs. 2018;32(4):335–50.
Djémié T, Weckhuysen S, Von Spiczak S, et al. Pitfalls in genetic testing: the story of missed SCN1A mutations. Mol Genet Genom Med. 2016;4(4):457–64.
Wirrell EC, Laux L, Donner E, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel. Pediatr Neurol. 2017;68(18–34):e3.
Ziobro J, Eschbach K, Sullivan JE, et al. Current treatment strategies and future treatment options for Dravet syndrome. Curr Treat Options Neurol. 2018;20(12):52 (1–15).
Plosker GL. Stiripentol: in severe myoclonic epilepsy of infancy (Dravet syndrome). CNS Drugs. 2012;26(11):993–1001.
Nickels KC, Wirrell EC. Stiripentol in the management of epilepsy. CNS Drugs. 2017;31(5):405–16.
Chiron C. Stiripentol for the treatment of seizures associated with Dravet syndrome. Expert Rev Neurother. 2019;19(4):301–10.
European Medicines Agency. Stiripentol (Diacomit): EU summary of product characteristics. 2018. https://www.ema.europa.eu/documents/product-information/diacomit-epar-product-information_en.pdf. Accessed 26 Feb 2019.
CRI. PrDiacomitTM (stiripentol capsules; powder for suspension): Canadian product monograph. 2012. https://pdf.hres.ca/dpd_pm/00022311.PDF. Accessed 26 Aug 2019.
Meiji Seika Pharma Co. Ltd. Stiripentol (Diacomit): Japanese prescribing information. 2013. http://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/1139011. Accessed 21 June 2019.
Biocodex Inc. Stiripentol (DIACOMIT): US prescribing Information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf. Accessed 26 Feb 2019.
Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356(9242):1638–42.
Guerrini R, Tonnelier S, d’Athis P, et al. Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled Italian trial [abstract no. P496]. Epilepsia. 2002;43(Suppl. 8):155.
Center for Drug Evaluation and Research. Application number: 206709Orig1s000 207223Orig1s000 Clin. Rev. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206709Orig1s000,207223Orig1s000MedR.pdf. Accessed 6 June 2019.
Kassai B, Chiron C, Augier S, et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia. 2008;49(2):343–8.
Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40(11):1618–26.
Inoue Y, Ohtsuka Y. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence. Epilepsy Res. 2014;108(4):725–31.
Inoue Y, Ohtsuka Y. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res. 2015;113:90–7.
Myers KA, Lightfoot P, Patil SG, et al. Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study. Dev Med Child Neurol. 2018;60(6):574–8.
Nabbout R, Copioli C, Chipaux M, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia. 2011;52(7):e54–7.
Thanh TN, Chiron C, Dellatolas G, et al. Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet’s syndrome). Arch Pediatr. 2002;9(11):1120–7.
Chiron C, Helias M, Kaminska A, et al. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood? Epilepsia. 2018;59(9):1705–17.
Inoue Y, Ohtsuka Y, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia. 2009;50(11):2362–8.
De Liso P, Chemaly N, Laschet J, et al. Patients with Dravet syndrome in the era of stiripentol: a French cohort cross-sectional study. Epilepsy Res. 2016;125:42–6.
Wirrell EC, Laux L, Franz DN, et al. Stiripentol in Dravet syndrome: results of a retrospective US study. Epilepsia. 2013;54(9):1595–604.
Cho MJ, Kwon SS, Ko A, et al. Efficacy of stiripentol in Dravet syndrome with or without SCN1A mutations. J Clin Neurol. 2018;14(1):22–8.
Yildiz EP, Ozkan MU, Uzunhan TA, et al. Efficacy of stiripentol and the clinical outcome in Dravet syndrome. J Child Neurol. 2019;34(1):33–7.
Dressler A, Trimmel-Schwahofer P, Reithofer E, et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome—comparison with various standard antiepileptic drug regimen. Epilepsy Res. 2015;109:81–9.
Balestrini S, Sisodiya SM. Audit of use of stiripentol in adults with Dravet syndrome. Acta Neurol Scand. 2017;135(1):73–9.
Chiron C. Stiripentol and vigabatrin current roles in the treatment of epilepsy. Expert Opin Pharmacother. 2016;17(8):1091–101.
Strzelczyk A, Schubert-Bast S, Reese JP, et al. Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam. Epilepsy Behav. 2014;34:86–91.
Rosander C, Hallbook T. Dravet syndrome in Sweden: a population-based study. Dev Med Child Neurol. 2015;57(7):628–33.
Aras LM, Isla J, Mingorance-Le Meur A. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome. Epilepsy Behav. 2015;44:104–9.
Schubert-Bast S, Wolff M, Wiemer-Kruel A, et al. Seizure management and prescription patterns of anticonvulsants in Dravet syndrome: a multicenter cohort study from Germany and review of literature. Epilepsy Behav. 2019;98(Pt A):88–95.
Wilmshurst JM, Gaillard WD, Vinayan KP, et al. Summary of recommendations for the management of infantile seizures: task force report for the ILAE Commission of Pediatrics. Epilepsia. 2015;56(8):1185–97.
Brunklaus A, Ellis R, Reavey E, et al. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain. 2012;135(Pt 8):2329–36.
European Medicines Agency. Cannabidiol (Epidyolex): EU summary of product characteristics. 2019. https://ec.europa.eu/health/documents/community-register/2019/20190919145790/anx_145790_en.pdf. Accessed 3 Oct 2019.
Greenwich Biosciences Inc. EPIDIOLEX® (cannabidiol): US prescribing Information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf. Accessed 26 Feb 2019.
Wirrell EC. Treatment of Dravet syndrome. Can J Neurol Sci. 2016;43(Suppl 3):S13–8.
Strzelczyk A, Kalski M, Bast T, et al. Burden-of-illness and cost-driving factors in Dravet syndrome patients and carers: a prospective, multicenter study from Germany. Eur J Paediatr Neurol. 2019;23(3):392–403.
Poisson M, Huguet F, Savattier A, et al. A new type of anticonvulsant, stiripentol—pharmacological profile and neurochemical study. Arzneimittel-Forschung/Drug Research. 1984;34(2):199–204.
Grosenbaugh DK, Mott DD. Stiripentol is anticonvulsant by potentiating GABAergic transmission in a model of benzodiazepine-refractory status epilepticus. Neuropharmacology. 2013;67:136–43.
Sada N, Lee S, Katsu T, et al. Epilepsy treatment: targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015;347(6228):1362–7.
Quilichini PP, Chiron C, Ben-Ari Y, et al. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA(A)-receptor channels. Epilepsia. 2006;47(4):704–16.
Fisher JL. The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology. 2009;56(1):190–7.
Fisher JL. The effects of stiripentol on GABA(A) receptors. Epilepsia. 2011;52(Suppl. 2):76–8.
Fisher JL. Interactions between modulators of the GABA(A) receptor: stiripentol and benzodiazepines. Eur J Pharmacol. 2011;654(2):160–5.
Verleye M, Buttigieg D, Steinschneider R. Neuroprotective activity of stiripentol with a possible involvement of voltage-dependent calcium and sodium channels. J Neurosci Res. 2016;94(2):179–89.
Peigne S, Rey E, Le Guern ME, et al. Reassessment of stiripentol pharmacokinetics in healthy adult volunteers. Epilepsy Res. 2014;108(5):909–16.
Peigne S, Chhun S, Tod M, et al. Population pharmacokinetics of stiripentol in paediatric patients with Dravet syndrome treated with stiripentol, valproate and clobazam combination therapy. Clin Pharmacokinet. 2018;57(6):739–48.
Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: In vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997;62(5):490–504.
Jogamoto T, Yamamoto Y, Fukuda M, et al. Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy. Epilepsy Res. 2017;130:7–12.
Yamamoto Y, Takahashi Y, Imai K, et al. Effect of CYP inducers/inhibitors on topiramate concentration: clinical value of therapeutic drug monitoring. Ther Drug Monit. 2017;39:55–61.
Ben-Menachem E, Gunning B, Cabrera CMA, et al. A phase 2 trial to explore the potential for a pharmacokinetic drug–drug interaction with stiripentol when in combination with cannabidiol (CBD) in patients with epilepsy [poster 338]. In: International epilepsy congress, 2019.
Morrison G, Crockett J, Blakey G, et al. A Phase 1, open-label, pharmacokinetic trial to investigate possible drug–drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharm Drug Dev. 2019. https://doi.org/10.1002/cpdd.665.
Acknowledgements
During the peer review process, the manufacturer of stiripentol was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Conflict of interest
James Frampton is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.
Additional information
Enhanced material for this Adis Drug Evaluation can be found at https://doi.org/10.6084/m9.figshare.9876596.
The manuscript was reviewed by:S. Balestrini, Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK; C. Chiron, INSERM U1141, Neurospin (CEA) and Neuropediatric Department, Necker Enfants-Malades Hospital, Paris, France; C. Dravet, Childhood Neuropsychiatry, Catholic University, Rome, Italy; A. Strzelczyk, Department of Neurology, Epilepsy Center Frankfurt Rhine‐Main, Goethe University, Frankfurt am Main, Germany; A. Verrotti, Department of Pediatrics, University of L’Aquila, L’Aquila, Italy.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Frampton, J.E. Stiripentol: A Review in Dravet Syndrome. Drugs 79, 1785–1796 (2019). https://doi.org/10.1007/s40265-019-01204-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-019-01204-y